{"id":60919,"date":"2025-03-12T13:02:40","date_gmt":"2025-03-12T12:02:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/"},"modified":"2025-03-12T13:02:40","modified_gmt":"2025-03-12T12:02:40","slug":"lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/","title":{"rendered":"LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories"},"content":{"rendered":"
\n

\n\u2014<\/i> Investment Expands Company\u2019s CDMO Facilities and Services to Meet Growing Demand for Domestic Drug Product Development and Manufacturing \u2014<\/i>\n<\/p>\n

\n\u2014<\/i> Learn More from Company Leadership at 2025 DCAT Week \u2014<\/i>\n<\/p>\n

BOCA RATON, Fla.–(BUSINESS WIRE)–#505b2<\/a>–LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing facility as part of its Phase I CDMO growth strategy. The expansion will increase capacity for liquid, suspension<\/a>, semi-solid<\/a>, and suppository drug products<\/a>, addressing the rising demand for reliable U.S.-based production.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThis investment comes as LGM Pharma experiences sustained growth in prescription drug projects, including 505(b)(2) and Abbreviated New Drug Application (ANDA) programs. The Rosenberg facility enhancements will accommodate increased production volumes while ensuring compliance with FDA regulations and current good manufacturing practices (cGMP). The site will remain fully operational throughout the expansion.\n<\/p>\n

\n\u201cLGM Pharma is making strategic investments to support the growing need for high-quality domestic drug manufacturing,\u201d said Prasad Raje, Ph.D., CEO of LGM Pharma. \u201cWe have several prescription products in development, including both 505(b)(2) and ANDA projects, with one ANDA already submitted to the FDA. This expansion ensures we can continue providing our customers with the quality, reliability, and confidence they need to bring these products to market.\u201d\n<\/p>\n

\nExpanding Capacity to Meet Market Demand<\/b>\n<\/p>\n

\nThe contract development and manufacturing market for liquid, suspension, semi-solid, and suppository drugs is projected to see significant growth over the next decade, with North American manufacturers playing a key role.1<\/sup> The U.S. and Canada suppositories market is projected to reach $1.3 billion by 2035, reflecting increasing acceptance of this dosage form.2<\/sup>\n<\/p>\n

\nLGM Pharma\u2019s investment will strengthen both infrastructure and quality systems at the Rosenberg facility, enhancing its ability to manufacture prescription drug products, including topical and suppository products, while maintaining the highest regulatory and quality standards.\n<\/p>\n

\nHamilton Lenox, Chief Commercial Officer of LGM Pharma, added, \u201cWe currently manufacture prescription products at our oral solid dose facility in Irvine, California. The Rosenberg expansion will elevate this site to the same high standards, allowing us to support customers developing liquid, suspension, semi-solid, and suppository prescription drug products with the same level of expertise and quality assurance from a U.S.-based manufacturing site.\u201d\n<\/p>\n

\nStrengthening U.S. Pharmaceutical Manufacturing<\/b>\n<\/p>\n

\nAs supply chain disruptions, tariffs, and global uncertainties continue to impact pharmaceutical manufacturing, LGM Pharma\u2019s investment provides a dependable domestic solution. The expansion also includes track and trace serialization capabilities at the Rosenberg facility, aligning with regulatory requirements to enhance product traceability and ensure compliance.\n<\/p>\n

\nCompanies developing 505(b)(2), NDA, ANDA, branded or generic prescription drug products are encouraged to explore LGM Pharma\u2019s expanded manufacturing capabilities by visiting LGMPharma.com<\/a> or meeting with company executives at DCAT Week<\/a> (March 17-20, 2025) in New York City.\n<\/p>\n\n\n\n\n\n
References:<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\n1.\n<\/p>\n<\/td>\n

<\/td>\n\n

\nPrecedence Research, “Topical Drugs CDMO Market,” <\/i>[updated Feb 4, 2025], https:\/\/www.precedenceresearch.com\/topical-drugs-cdmo-market<\/a>.\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2.\n<\/p>\n<\/td>\n

<\/td>\n\n

\nAllied Market Research, “U.S. and Canada Pharmaceutical Suppositories Market,”<\/i> [Nov 2024], https:\/\/www.alliedmarketresearch.com\/us-and-canada-pharmaceutical-suppositories-market-A325457<\/a>.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAbout LGM Pharma<\/b>\n<\/p>\n

\nLGM Pharma is a leading contract development and manufacturing organization (CDMO) providing comprehensive Active Pharmaceutical Ingredient (API) sourcing, drug product CDMO services, and contract analytical testing services to the pharmaceutical, biotechnology, and compounding pharmacy industries. LGM Pharma assists clients in managing all phases of the drug product development process, from API sourcing through to drug product commercialization. LGM Pharma\u2019s extensive global network of qualified API partners enables clients to optimize supply chain management and distribution. Services include API sourcing and procurement, formulation development, analytical method development, method and process validation, ANDA \/ NDA submission, stability studies, and raw material and finished product testing and packaging. LGM Pharma is committed to quality and has a long-established positive regulatory track record, providing expert regulatory and market intelligence services to its clients. The company is focused on customer service and customized solutions, providing clients with a comprehensive U.S.-based manufacturing solution that reduces risk, increases efficiency, and accelerates the path to commercialization. For more information, visit LGMPharma.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Charya Wickremasinghe, Ph.D.
\n
Brandwidth Solutions LLC
\n
cwickremasinghe@brandwidthsolutions.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2014 Investment Expands Company\u2019s CDMO Facilities and Services to Meet Growing Demand for Domestic Drug Product Development and Manufacturing \u2014 \u2014 Learn More from Company Leadership at 2025 DCAT Week \u2014 BOCA RATON, Fla.–(BUSINESS WIRE)–#505b2–LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-60919","format-standard","category-industry"],"yoast_head":"\nLGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2014 Investment Expands Company\u2019s CDMO Facilities and Services to Meet Growing Demand for Domestic Drug Product Development and Manufacturing \u2014 \u2014 Learn More from Company Leadership at 2025 DCAT Week \u2014 BOCA RATON, Fla.–(BUSINESS WIRE)–#505b2–LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-12T12:02:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250312785272\/en\/2399816\/22\/LGM_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories\",\"datePublished\":\"2025-03-12T12:02:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/\"},\"wordCount\":694,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250312785272\\\/en\\\/2399816\\\/22\\\/LGM_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/\",\"name\":\"LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250312785272\\\/en\\\/2399816\\\/22\\\/LGM_Logo.jpg\",\"datePublished\":\"2025-03-12T12:02:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250312785272\\\/en\\\/2399816\\\/22\\\/LGM_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250312785272\\\/en\\\/2399816\\\/22\\\/LGM_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/","og_locale":"en_US","og_type":"article","og_title":"LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories - Pharma Trend","og_description":"\u2014 Investment Expands Company\u2019s CDMO Facilities and Services to Meet Growing Demand for Domestic Drug Product Development and Manufacturing \u2014 \u2014 Learn More from Company Leadership at 2025 DCAT Week \u2014 BOCA RATON, Fla.–(BUSINESS WIRE)–#505b2–LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/","og_site_name":"Pharma Trend","article_published_time":"2025-03-12T12:02:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250312785272\/en\/2399816\/22\/LGM_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories","datePublished":"2025-03-12T12:02:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/"},"wordCount":694,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250312785272\/en\/2399816\/22\/LGM_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/","url":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/","name":"LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250312785272\/en\/2399816\/22\/LGM_Logo.jpg","datePublished":"2025-03-12T12:02:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250312785272\/en\/2399816\/22\/LGM_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250312785272\/en\/2399816\/22\/LGM_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lgm-pharma-invests-6m-in-u-s-drug-manufacturing-capabilities-for-liquids-suspensions-semi-solids-and-suppositories\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities for Liquids, Suspensions, Semi-Solids, and Suppositories"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60919"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60919\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}